Hepatocellular carcinoma

41 trials 16 recruiting MedDRA PT
41 Registered trials
16 Recruiting
26 Unique sponsors
34 Unique IMPs
32 Commercial trials
Drug classes (ATC)
— ATC code not specified 21
L Oncology (ATC L) 21
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 12 substances
Checkpoint inhibitor (PD-L1) 2 substances
Checkpoint inhibitor (CTLA-4) 2 substances
Kinase inhibitor 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Monoclonal antibody (immune) 2 substances
Anthracycline 2 substances
Monoclonal antibody (angiogenesis) 1 substance
Platinum compound 1 substance
Antimetabolite 1 substance
Monoclonal antibody (chimeric) 1 substance
Immunosuppressant 1 substance
RAF/BRAF inhibitor 1 substance
CDK inhibitor 1 substance
Antibody-drug conjugate (ADC) 1 substance
Taxane 1 substance
Monoclonal antibody (human) 1 substance
Phase III: 10 Phase II: 6 Phase I/II: 11 Phase I: 8 Phase I (Other): 5 Phase I (First in Human): 2

Filter these 41 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 41 trials

Phase III

10 trials
  • AstraZeneca AB Commercial
    DURVALUMAB; INFLIXIMAB; TREMELIMUMAB
    2022-502012-37-00 4 countries 2023 n=89
    Ended
  • AstraZeneca AB Commercial
    RILVEGOSTOMIG; TREMELIMUMAB
    2024-518210-81-00 6 countries 2026 n=273
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IPILIMUMAB; NIVOLUMAB; SORAFENIB
    2023-508635-31-00 8 countries 2019 n=373
    Ended
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    NIVOLUMAB
    2023-508726-10-00 8 countries 2018 n=145
    Ended
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB; BEVACIZUMAB
    2023-504303-86-00 9 countries 2019 n=72
    Ended
  • Merck Sharp & Dohme LLC Commercial
    LENVATINIB; PEMBROLIZUMAB
    2022-502116-36-00 9 countries 2020 n=200
    Ended
  • Shanghai Junshi Biosciences Co. Ltd. Commercial
    LENVATINIB; TORIPALIMAB
    2024-514207-34-00 2 countries 2021 n=22
    Ended
  • Centre Hospitalier Universitaire De Nantes Academic
    IMP not specified
    2024-519505-35-00 1 country 2026 n=28
    Recruiting
  • The University Of Birmingham Academic
    IMP not specified
    2024-516110-38-00 10 countries 2018 n=292
    Recruiting
  • Unicancer Academic
    IMP not specified
    2024-513707-14-00 1 country 2022 n=646
    Ended

Phase II

6 trials
  • AstraZeneca AB Commercial
    BEVACIZUMAB; CISPLATIN; GEMCITABINE; INFLIXIMAB; LENVATINIB; MYCOPHENOLATE MOFETIL; RILVEGOSTOMIG; VOLRUSTOMIG
    2022-502317-29-00 2 countries 2023 n=60
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB; RELATLIMAB
    2023-503519-13-00 5 countries 2020 n=109
    Ended
  • Centre Hospitalier Universitaire De Nantes Academic
    ETHYL ESTERS OF IODISED FATTY ACIDS FROM POPPYSEED OIL; IDARUBICIN HYDROCHLORIDE
    2024-515456-20-00 1 country 2024 n=53
    Recruiting
  • Centre Hospitalier Universitaire De Nantes Academic
    IMP not specified
    2024-519113-59-00 1 country 2024 n=202
    Recruiting
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic
    DURVALUMAB
    2024-513950-32-00 1 country 2020 n=55
    Recruiting
  • Humanitas Mirasole S.p.A. Academic
    CABOZANTINIB
    2024-516972-14-00 1 country 2020 n=46
    Ended

Phase I/II

11 trials
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB
    2023-503554-12-00 5 countries 2019 n=96
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB; NIVOLUMAB, RELATLIMAB; RELATLIMAB
    2023-508067-70-00 9 countries 2015 n=1,003
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    BEVACIZUMAB; NIVOLUMAB; RELATLIMAB
    2024-510649-33-00 5 countries 2022 n=53
    Ended
  • Cyclacel Limited Commercial
    FADRACICLIB
    2024-516289-12-00 1 country 2022 n=30
    Ended
  • Cyclacel Limited Commercial
    CYC140 MONOHYDROCHLORIDE MONOHYDRATE
    2024-516290-67-00 1 country 2022 n=56
    Ended
  • Daiichi Sankyo Inc. Commercial
    IFINATAMAB DERUXTECAN
    2023-509632-26-00 9 countries 2025 n=311 Orphan
    Recruiting
  • Eisai Limited Commercial
    (6S,9AS)-8-((6-(3-(4-ETHYL-1-PIPERAZINYL)-1-AZETIDINYL)-2-PYRIDINYL)METHYL)-6-((2-FLUORO-4-HYDROXYPHENYL)METHYL)HEXAHYDRO-4,7-DIOXO-N-(PHENYLMETHYL)-2-(2-PROPEN-1-YL)-2H-PYRAZINO(2,1-C)(1,2,4)TRIAZINE-1(6H)-CARBOXAMIDE; LENVATINIB; PEMBROLIZUMAB
    2023-505425-14-00 1 country 2022 n=30
    Ended
  • Eisai Limited Commercial
    (6S,9AS)-8-((6-(3-(4-ETHYL-1-PIPERAZINYL)-1-AZETIDINYL)-2-PYRIDINYL)METHYL)-6-((2-FLUORO-4-HYDROXYPHENYL)METHYL)HEXAHYDRO-4,7-DIOXO-N-(PHENYLMETHYL)-2-(2-PROPEN-1-YL)-2H-PYRAZINO(2,1-C)(1,2,4)TRIAZINE-1(6H)-CARBOXAMIDE; DOXORUBICIN HYDROCHLORIDE; LENVATINIB; PACLITAXEL
    2023-510275-64-00 4 countries 2023 n=83
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB; BEVACIZUMAB; RO7247669; TIRAGOLUMAB
    2022-502840-11-00 4 countries 2023 n=55
    Ended
  • Institut Gustave Roussy Academic
    IMP not specified
    2023-506156-25-00 1 country 2020 n=30
    Ended
  • Institut Gustave Roussy Academic
    IMP not specified
    2023-506156-25-00 1 country 2020 n=30
    Ended

Phase I

8 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2024-518012-39-00 1 country 2025 n=20
    Recruiting
  • Alnylam Pharmaceuticals Inc. Commercial
    IMP not specified
    2024-519499-22-00 1 country 2025 n=31
    Recruiting
  • Bayer Consumer Care AG Commercial
    IMP not specified
    2024-516615-25-00 4 countries 2025 n=123
    Recruiting
  • Beigene Ltd. Commercial
    IMP not specified
    2023-503996-38-00 1 country 2025 n=60
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2025-524136-19-00 2 countries 2026 n=56
    Recruiting
  • Captor Therapeutics S.A. Commercial
    IMP not specified
    2024-511435-10-00 3 countries 2025 n=154
    Recruiting
  • Seagen Inc. Commercial
    IMP not specified
    2023-506604-18-00 6 countries 2024 n=177
    Recruiting
  • Incyte Corp. Academic
    IMP not specified
    2023-504400-29-00 1 country 2022 n=9
    Ended

Phase I (Other)

5 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-506227-29-00 2 countries 2024 n=60
    Recruiting
  • AstraZeneca AB Commercial
    CERALASERTIB; DURVALUMAB; DURVALUMAB, HYALURONIDASE (HUMAN RECOMBINANT); TREMELIMUMAB
    2025-521639-34-00 1 country 2026 n=4
    Recruiting
  • Disruptive Pharma AB Commercial
    IMP not specified
    2024-514496-18-00 1 country n=20
    Not authorised
  • Disruptive Pharma AB Commercial
    IMP not specified
    2024-514496-18-01 1 country 2025 n=12
    Ended
  • Incyte Corp. Commercial
    INCB099280; IPILIMUMAB
    2023-503243-34-00 3 countries n=23
    Ended

Phase I (First in Human)

2 trials
  • Crescent Biopharma Inc. Commercial
    CR-001
    2025-523590-42-00 1 country n=44
    Pending
  • Salubris Biotherapeutics Inc. Commercial
    JK08; LENVATINIB; PEMBROLIZUMAB
    2024-511750-53-00 2 countries 2022 n=130
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AstraZeneca AB Commercial 4 Phase I (Other), Phase II, Phase III 2
Bristol Myers Squibb International Corporation Commercial 4 Phase II, Phase I/II 0
Centre Hospitalier Universitaire De Nantes Academic 3 Phase II, Phase III 3
AbbVie Deutschland GmbH & Co. KG Commercial 2 Phase I, Phase I (Other) 2
Disruptive Pharma AB Commercial 2 Phase I (Other) 0
Incyte Corp. Commercial 2 Phase I (Other), Phase I 0
Bristol-Myers Squibb Services Unlimited Company Commercial 2 Phase III 0
F. Hoffmann-La Roche AG Commercial 2 Phase III, Phase I/II 0
Cyclacel Limited Commercial 2 Phase I/II 0
Eisai Limited Commercial 2 Phase I/II 1
Institut Gustave Roussy Academic 2 Phase I/II 0
Alnylam Pharmaceuticals Inc. Commercial 1 Phase I 1
Bayer Consumer Care AG Commercial 1 Phase I 1
Beigene Ltd. Commercial 1 Phase I 0
BeOne Medicines AG Commercial 1 Phase I 1
Captor Therapeutics S.A. Commercial 1 Phase I 1
Seagen Inc. Commercial 1 Phase I 1
Merck Sharp & Dohme LLC Commercial 1 Phase III 0
Shanghai Junshi Biosciences Co. Ltd. Commercial 1 Phase III 0
Crescent Biopharma Inc. Commercial 1 Phase I (First in Human) 0
New trials by year
2019
3
2020
6
2021
1
2022
7
2023
4
2024
4
2025
7
2026
4
← All indication landscapes